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Even though the range of gene therapy strategies is quite diverse, certain key elements are required for a successful gene therapy strategy. The most elementary of these is that the relevant gene must be identi®ed and cloned. Upon completion of the Human Genome Project, gene availability will be unlimited, but until then the starting point for any gene therapy strategy remains gene identi®cation and cloning for relevant genes related to the disease.
Once the gene has been identi®ed and cloned, the next consideration must be expression. Questions pertaining to the ef®ciency of gene transfer and gene expression remain at the forefront of gene therapy research. Currently, much debate in the ®eld of gene therapy revolves around the transfer of desired genes to appropriate cells, and then obtaining suf®cient levels of expression for disease treatment. Hopefully, future research on gene transfer and tissue-speci®c gene expression will resolve these issues. Other important considerations for a gene therapy strategy include: a suf®cient understanding of the pathogenesis of the targeted disorder, potential side effects of the gene therapy treatment, and understanding of the target cells to receive the gene therapy.
The advances in molecular biology have helped the identi®cation, isolation, sequencing, cloning and expression of numerous genes and gene products. The tools used in molecular biology such as Northern, Western and Southern blots and the polymerase chain reaction have also allowed more precise evaluation of the contributions of individual genes to cellular responses. The extremely ®delity of replications of genetic material and the relative ease of introducing these material in many cells in vitro has made gene therapy an attractive therapeutic option in many medical ®elds.
The past two decades have seen revolutional changes in the treatment of erectile dysfunction from the invention of penile prosthesis to the development of intracavernous injection and oral agent. However, despite their ef®cacy, all treatments have signi®cant drawbacks and side effects. On the other hand, gene therapy has the potential to be the best and most physiologic treatment for erectile dysfunction.
Since smooth muscle relaxation is the ®nal step for penile erections, many molecules and enzymes in the signal transduction pathway for smooth muscle relaxation can be potential targets for the treatment of erectile dysfunction, e.g. nitric oxide synthase (NOS) and the potassium channel (maxi-K channel, hSlo). In addition, many growth factors have been shown to enhance angiogenesis and regeneration of nerves and thus can also be used to treat vasculogenic or neurogenic impotence. The most common used vehicles for gene transfer are: (1) Plasmid DNA vector (naked DNA) or liposome-DNA complexes; and (2) viral vectors (retrovirus, adenovirus and adeno-associated virus).
Theoretically, the penis is an ideal organ for gene therapy because of its external location and slow circulation. Several groups of researches have successfully performed gene therapy in animal experiments to date. Garban and associates 2 transfected nitric oxide gene into old rats' penis and were able to improve erection in those rats. Christ et al 3 performed gene therapy with potassium channel opener and showed signi®cantly improved erection in diabetic rats. Huard et al 4 showed that myoblast mediated gene therapy was more successful in delivering iNOS into the rat penis than direct virus or plasmid transfection methods. Wessells and Williams 5 also showed successful endothelial cell transplantation into the corpus cavernosum and suggest that it may be a more ef®cient method of gene transfer.
Cavernous nerve injury resulting in erectile dysfunction (ED) is common in post radical pelvic surgery patients. We have studied the feasibility of using growth hormone to enhance the cavernous nerve recovery in the rats. The results were quite exciting since many of the rats recovered erectile function much faster and more completely than those not receiving growth hormone. In another animal experiments, we have also successfully restored erectile function in rats which had undergone ligation of both internal iliac arteries. Two experiments were performed: one with VEGF-165, the other with adeno-associated virus-VEGF. Both were injected into the corpus cavernosum several minutes after the internal iliac arteries were ligated. In the VEGF treated group, the erectile function was restored at week 6. In the AAV-VEGF group, the function did not return until week 9 because of the delayed production of VEGF by the transfected VEGF gene. The control groups only showed minimal restoration of erectile function.
Although gene therapy is an exciting method of restoring erectile function, regulatory approval may not allow its use for many years to come. However, many of the growth factors known to enhance nerve growth and angiogenesis are available for clinical use today and may become the best preventive and therapeutic option in the next decade.
